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Identity 
 
t(11;16)(q23;p13.3) G-banding. 
Clinics and pathology 
Disease 
Treatment-related myelodysplastic syndrome (t-MDS) 
or treatment-related acute leukaemia, usually 
myeloblastic (t-AML), less often lymphoblastic (t-
ALL). 
Two case reports describe a de novo leukaemia with 
t(11;16)(q23;p13.3): an AML-M4 (Glassman et al., 
2003) and an infant ALL, which switch into AML with 
retention of the translocation (Stasik et al., 2006). 
Phenotype/cell stem origin 
Variable phenotypes: most often LAM4 in t-AML (but 
also LAM5a and LAM2); chronic myelomono-cytic 
leukaemia (CMMoL) in t-MDS. 
Etiology 
Chemotherapy for other primary malignancies 
(including leukaemia, lymphoma and solid tumors) 
using topoisomerase II inhibitors (epipodophyllo-toxins 
or anthracyclins). 
Epidemiology 
Rare translocation (about twenty cases described), 
found at any age, from infancy to elder age. 
Prognosis 
Poor, as in other therapy-related leukaemia. 
Cytogenetics 
Cytogenetics morphological 
Can be seen with G-banding: chromosome 11 appears 
shortened, chromosome 16 enlarged (11q- and 16p+). 
Cytogenetics molecular 
FISH may be needed. 
Additional anomalies 
In half cases about, no recurrent additional cytogenetic 
anomalies. 
Genes involved and proteins 
MLL 
Location 
11q23 
DNA/RNA 
37 exons, spanning over 100 kb. 
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Fish studies using a commercially available MLL break-apart probe (Vysis® LSI® MLL Dual Color). The derivative 11 shows a single 
green signal indicating rearrangement of the MLL locus. The derivative 16 has the translocated portion of the MLL indicated by a single 
red signal. 
 
Protein 
MLL is a "multipartner" gene involved in multiple 
rearrangements: the most frequent partners are AF4 in 
4q21, AF6 in 6q27, AF9 in 9p22, ELL in 19p13.1 and 
ENL in 19p13.3. 
MLL is a major regulator of hematopoesis and 
embryonic development, through HOX genes 
expression regulation. MLL binds to promotors of 
HOX genes such as Hoxa7 and Hoxa9 (proteins which 
regulate hematopoiesis and are normally expressed 
only in early hematopoietic progenitors) through 
acetylation and methylation of histones. 
CBP (CREB-binding protein) 
Location 
16p13.3 
DNA/RNA 
About 154 kb, 32 exons. 
Protein 
It is a transcriptional coactivator involved in 
coordonating signal from many sequence-specific 
activators to modulate transcription and/or cell cycle 
progression. It has endogenous histone acetyl-
transferase activity and may contribute to trans-
criptional regulation via targeted acetylation of 
chromatin. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Transcript 
5' MLL - 3' CBP on the der(11) and 5' CBP - 3' MLL 
on the der(16). 
Variable breakpoints: In MLL, almost all of the  
breakpoints occurs in an 8.3-kb fragment known as the 
breakpoint cluster region (BCR), encompassing exons 
8-14. In CBP, the genomic breakpoints clustered in an 
8.2-kb region of intron 3 (BCR 8.2kb), which is 
different of the breakpoints in CBP for patients with 
t(8;16) clustered in a 2.3-kb region in intron 2 (BCR 
2.3kb). 
Fusion protein 
Description 
N-Term from MLL (containing the AT-hooks and 
repression domain) fused to the C-Term of CBP 
(almost always including the CREB binding domain, 
bromodomain, histone acetyltransferase domain). 
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